Juvenile myelomonocytic leukemia (JMML) is a rare, clonal myeloproliferative disorder afflicting young children. Since 1986 a team of investigators at the University of Alabama at Birmingham (UAB) have been conducting translational research studies in JMML. Over the last ten years the UAB JMML project has risen to the forefront of research in this rare but fascinating disorder. The blend of investigators in basic science and clinical investigation has positioned the UAB team in a unique role to have unprecedented access to JMML patients and thus take a leadership role in investigating mechanism-based treatment modalities. The pathogenesis of JMML has been linked to deregulated GM-CSF growth factor signal transduction through the Ras pathway. This deregulation results in JMML cells demonstrating selective hypersensitivity to GM-CSF in vitro. This feature of growth factor hypersensitivity is emerging as a potential common mechanism amongst many other myeloproliferative disorders and thus, JMML serves as an important model disease. Potential causative mutations resulting in GM-CSF hypersensitivity include neurofibromatosis gene abnormalities in 30 percent of JMML patients and RAS mutations in an additional 20 percent of patients. Causative mutations are undefined in the remaining majority of patients. In addition to providing insights into the pathogenesis of this disease, the UAB JMML project has also identified a promising new treatment modality using 13-cis retinoic acid (CRA). The retinoic acid appears to modulate the hypersensitive GM-CSF response in JMML. But CRA does not appear to be effective enough to induce complete, lasting remissions. Thus there is a need for more effective therapeutics and such strategies can be aimed at the GM-CSF pathway as a result of the pathogenetic studies. The major goals for the recipient of this K24 award will be: (1) to establish the first North American JMML Registry at the P.I.'s institution and the first Pediatric Intergroup Multimodality Clinical Trials Program for JMML, (2) to complete the development of a diagnostic test for JMML, field test it and implement it, (3) to continue to investigate for other genetic mutations in the Ras signaling pathway responsible for GM-CSF hypersensitivity within JMML cells, and (4) to develop other novel therapeutic strategies for JMML that are mechanism-based.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24CA080916-04
Application #
6513497
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1999-05-13
Project End
2004-04-30
Budget Start
2002-05-01
Budget End
2003-04-30
Support Year
4
Fiscal Year
2002
Total Cost
$84,957
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Liu, Yunying Lucy; Castleberry, Robert P; Emanuel, Peter D (2009) PTEN deficiency is a common defect in juvenile myelomonocytic leukemia. Leuk Res 33:671-7
Archambeault, Sophie; Flores, Nikki J; Yoshimi, Ayami et al. (2008) Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood 111:1124-7
Stephens, Karen; Weaver, Molly; Leppig, Kathleen A et al. (2006) Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood 108:1684-9
Gratias, Eric J; Liu, Y Lucy; Meleth, Sreelatha et al. (2005) Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia. Pediatr Blood Cancer 44:142-6
Meng, Zheng; King, Peter H; Nabors, L Burt et al. (2005) The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Res 33:2962-79
Kratz, Christian P; Niemeyer, Charlotte M; Castleberry, Robert P et al. (2005) The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 106:2183-5
Loh, Mignon L; Vattikuti, Shashaank; Schubbert, Suzanne et al. (2004) Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103:2325-31
Metelitsa, L S; Weinberg, K I; Emanuel, P D et al. (2003) Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 17:1068-77
Blume, Scott W; Miller, Donald M; Guarcello, Vincenzo et al. (2003) Inhibition of tumorigenicity by the 5'-untranslated RNA of the human c-myc P0 transcript. Exp Cell Res 288:131-42
Meng, Zheng; Snyder, Richard C; Shrestha, Kedar et al. (2003) Evidence for differential ribonucleoprotein complex assembly in vitro on the 5'-untranslated region of the human IGF-IR transcript. Mol Cell Endocrinol 200:127-40

Showing the most recent 10 out of 13 publications